MAPT and amyloidosis: Current standard cerebrospinal fluid (CSF) markers for AD in the DS population are restricted to surrogate markers of amyloidosis (Aβ42:40 ratio, Aβ1-42) and tau-mediated neurodegeneration (p-tau) and neurofilament light chain combined with neuropsychological assessment.